Chemokines and Gynecologic Malignancies

[1]  F. Balkwill,et al.  Hypoxia down‐regulates MCP‐1 expression: implications for macrophage distribution in tumors , 1998, Journal of leukocyte biology.

[2]  James J. Campbell,et al.  Multistep Navigation and the Combinatorial Control of Leukocyte Chemotaxis , 1997, The Journal of cell biology.

[3]  J. Krauss,et al.  Monocyte chemoattractant protein inhibits the generation of tumor-reactive T cells. , 1997, Cancer research.

[4]  G. Parham,et al.  The national cancer data base report on malignant epithelial ovarian carcinoma in African‐American women , 1997, Cancer.

[5]  T. Shono,et al.  Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis , 1997, Molecular and cellular biology.

[6]  D. Hornung,et al.  Immunolocalization and regulation of the chemokine RANTES in human endometrial and endometriosis tissues and cells. , 1997, The Journal of clinical endocrinology and metabolism.

[7]  M. Krasnow,et al.  The Hypoxic Response: Huffing and HIFing , 1997, Cell.

[8]  Rakesh K. Jain,et al.  Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation , 1997, Nature Medicine.

[9]  R. Freedman,et al.  HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2. , 1996, Cellular immunology.

[10]  J. Gribben,et al.  Breast cancer–associated antigen, DF3/MUC1, induces apoptosis of activated human T cells , 1996, Nature Medicine.

[11]  P. Galle,et al.  Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion? , 1996, Nature Medicine.

[12]  T. Whiteside,et al.  Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma , 1996, International journal of cancer.

[13]  J. Ting,et al.  Taxol-dependent Transcriptional Activation of IL-8 Expression in a Subset of Human Ovarian Cancer , 1996 .

[14]  J. Ludlow,et al.  Hypoxia arrests ovarian carcinoma cell cycle progression, but invasion is unaffected. , 1996, Cancer research.

[15]  J. Radke,et al.  Zytokinspiegel im malignen Aszites und peripheren Blut von Patientinnen mit fortgeschrittenem Ovarialkarzinom , 1996 .

[16]  B. Ebert,et al.  Isoenzyme-specific regulation of genes involved in energy metabolism by hypoxia: similarities with the regulation of erythropoietin. , 1996, The Biochemical journal.

[17]  A. Eggermont,et al.  Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. , 1995, Journal of the National Cancer Institute.

[18]  S. Ménard,et al.  An in vivo model to compare human leukocyte infiltration in carcinoma xenografts producing different chemokines , 1995, International journal of cancer.

[19]  G. Stamp,et al.  The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. , 1995, The Journal of clinical investigation.

[20]  J. Overgaard,et al.  The importance of determining necrotic fraction when studying the effect of tumour volume on tissue oxygenation. , 1995, Acta oncologica.

[21]  W. Hoskins.  Prospective on ovarian cancer: Why prevent? , 1995, Journal of cellular biochemistry. Supplement.

[22]  B. Ebert,et al.  Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents. , 1995, The American journal of physiology.

[23]  R. Scully.  Pathology of ovarian cancer precursors , 1995, Journal of cellular biochemistry. Supplement.

[24]  G. Tortolero-Luna,et al.  The epidemiology of ovarian cancer , 1995, Journal of cellular biochemistry. Supplement.

[25]  E. Adashi,et al.  Adverse Effects of Fertility Drugs , 1994, Drug safety.

[26]  J. Gribben,et al.  Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. , 1994, Blood.

[27]  H. Risch,et al.  Parity, contraception, infertility, and the risk of epithelial ovarian cancer. , 1994, American journal of epidemiology.

[28]  N. Teng,et al.  FACS analysis of peritoneal lymphocytes in ovarian cancer and control patients. , 1994, Immunobiology.

[29]  L. Pusztai,et al.  Expression of tumour necrosis factor alpha and its receptors in carcinoma of the breast. , 1994, British Journal of Cancer.

[30]  M. Herlyn,et al.  Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes , 1994, International journal of cancer.

[31]  F. Beuvon,et al.  Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. , 1994, Journal of the National Cancer Institute.

[32]  M. Piontek,et al.  Vascularization of carcinomas of the esophagus and its correlation with tumor proliferation. , 1994, Cancer research.

[33]  S M Bentzen,et al.  Measurement of human tumour oxygenation status by a polarographic needle electrode. An analysis of inter- and intratumour heterogeneity. , 1994, Acta oncologica.

[34]  T. Irimura,et al.  Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. , 1993, Journal of immunology.

[35]  W. Foulkes,et al.  Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. , 1993, The Journal of clinical investigation.

[36]  Robert C. Bast,et al.  Tumor Necrosis Factor α as an Autocrine and Paracrine Growth Factor for Ovarian Cancer: Monokine Induction of Tumor Cell Proliferation and Tumor Necrosis Factor α Expression , 1993 .

[37]  P. Ruck,et al.  Dysgerminoma of the ovary an immunohistochemical study of tumor‐infiltrating lymphoreticular cells and tumor cells , 1993, Cancer.

[38]  D. Thomas,et al.  Lactation and the risk of epithelial ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. , 1993, International journal of epidemiology.

[39]  P. Kenemans,et al.  The cellular composition in the peritoneal cavity and the cytotoxic function of the peritoneal cells from patients with ovarian cancer; effect of tumor necrosis factor-alpha treatment. , 1993, Cancer letters.

[40]  O. Gratzl,et al.  Cytokine gene expression in primary brain tumours, metastases and meningiomas suggests specific transcription patterns. , 1993, European journal of cancer.

[41]  B. Woda,et al.  Characterization of the inflammatory cell populations in normal colon and colonic carcinomas , 1993, Virchows Archiv. B, Cell pathology including molecular pathology.

[42]  P. Humphrey,et al.  Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. , 1992, Journal of the National Cancer Institute.

[43]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[44]  G. Fleuren,et al.  Tumor infiltrating cells in human cancer. On the possible role of CD16+ macrophages in antitumor cytotoxicity. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[45]  B. Sheid.  Angiogenic effects of macrophages isolated from ascitic fluid aspirated from women with advanced ovarian cancer. , 1992, Cancer letters.

[46]  M. Brunda,et al.  Tumoricidal activity and cytokine secretion by tumor‐infiltrating macrophages , 1991, International journal of cancer.

[47]  A. Sica,et al.  A chemoattractant expressed in human sarcoma cells (tumor‐derived chemotactic factor, TDCF) is identical to monocyte chemoattractant protein‐1/monocyte chemotactic and activating factor (MCP‐1/MCAF) , 1990, International journal of cancer.

[48]  E. Lotzová.  Role of human circulating and tumor-infiltrating lymphocytes in cancer defense and treatment. , 1990, Natural immunity and cell growth regulation.

[49]  A. Mantovani,et al.  IL‐1 and IL‐6 release by tumor‐associated macrophages from human ovarian carcinoma , 1989, International journal of cancer.

[50]  W. Fiers,et al.  Paradoxical effects of tumour necrosis factor in experimental ovarian cancer , 1989, International journal of cancer.

[51]  V. Beral,et al.  Risk factors for ovarian cancer: a case-control study. , 1989, British Journal of Cancer.

[52]  A. J. Valente,et al.  Identification of monocyte chemotactic activity produced by malignant cells. , 1989, Science.

[53]  J. Kovach,et al.  Phenotypic and functional characteristics of mononuclear cells in ovarian carcinoma tumors , 1989, Gynecologic oncology.

[54]  J. Kuratsu,et al.  Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants , 1989, The Journal of experimental medicine.

[55]  M. Yamada,et al.  Cloning and sequencing of the cDNA for human monocyte chemotactic and activating factor (MCAF). , 1989, Biochemical and biophysical research communications.

[56]  E. Appella,et al.  Human monocyte chemoattractant protein‐1 (MCP‐1) Full‐length cDNA cloning, expression in mitogen‐stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE , 1989, FEBS letters.

[57]  M. Goldberg,et al.  Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. , 1988, Science.

[58]  J. Sloane,et al.  An immunohistological study of leukocyte localization in benign and malignant breast tissue , 1985, International journal of cancer.

[59]  A. Mantovani,et al.  Tumor‐derived chemotactic factor(S) from human ovarian carcinoma: Evidence for a role in the regulation of macrophage content of neoplastic tissues , 1985, International journal of cancer.

[60]  R. Bast,et al.  Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms , 1983, International journal of cancer.

[61]  A. Mantovani,et al.  Chemotactic activity for mononuclear phagocytes of culture supernatants from murine and human tumor cells: Evidence for a role in the regulation of the macrophage content of neoplastic tissues , 1983, International journal of cancer.

[62]  B. Fisher.  Mononuclear-cell infiltration in ovarian cancer. I. Inflammatory-cell infiltrates from tumour and ascites material. , 1982, British journal of cancer.

[63]  S. Haskill,et al.  Mononuclear-cell infiltration in ovarian cancer. III. Suppressor-cell and ADCC activity of macrophages from ascitic and solid ovarian tumours. , 1982, British Journal of Cancer.

[64]  A. Mantovani,et al.  In vitro effects on tumor cells of macrophages isolated from an early‐passage chemically‐induced murine sarcoma and from its spontaneous metastases , 1981, International journal of cancer.

[65]  T. Tötterman,et al.  Cytological and functional analysis of inflammatory infiltrates in human malignant tumors. III. Further functional investigations using cultured autochthonous tumor cell lines and freeze-thawed infiltrating inflammatory cells. , 1980, Cellular immunology.

[66]  H. Svaar,et al.  Isolation and characterization of lymphocytes and macrophages from solid, malignant human tumours , 1979, International journal of cancer.

[67]  T. Tötterman,et al.  Cytological and functional analysis of inflammatory infiltrates in human malignant tumors II. Functional investigations of the infiltrating inflammatory cells , 1978, European journal of immunology.

[68]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[69]  J. Underwood.  Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review. , 1974, British Journal of Cancer.